Dolphin Entertainment, Inc. (DLPN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated October 31, 2023, reports on a material definitive agreement entered into by Dolphin Entertainment, Inc. The company, incorporated in Florida and trading on the Nasdaq Capital Market under the symbol DLPN, announced the pricing and execution of an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Underwritten public offering of common stock.
- Shares Issued: 1,400,000 shares of common stock ($0.015 par value).
- Offering Price: $1.65 per share.
- Gross Proceeds: Approximately $2,310,000.
- Over-Allotment Option: The underwriter (Maxim Group LLC) was granted a 45-day option to purchase an additional 210,000 shares.
- Closing Date: November 2, 2023.
- Use of Proceeds: Working capital, general corporate purposes, and potential acquisition or investment in complementary businesses.
Note: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's ongoing operations.
Material Changes
The primary material change is the increase in equity capital through the issuance of new shares. The filing does not provide comparative financial data against prior periods as it is a transaction-specific report rather than a periodic financial statement.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to support working capital needs and explore strategic growth opportunities through acquisitions or investments in complementary businesses. The offering was conducted pursuant to an effective shelf registration statement (Form S-3) filed in July 2023. The Underwriting Agreement includes customary representations, warranties, indemnification provisions, and termination clauses.
Key Facts for Investor Verification
- Verify the final net proceeds after deducting underwriting discounts, commissions, and offering expenses, as only gross proceeds ($2,310,000) are stated in this summary.
- Confirm whether the underwriter exercised the 210,000 share over-allotment option within the 45-day window.
- Review the final prospectus supplement (filed November 1, 2023) for detailed risk factors and use of proceeds specifics.
- Check subsequent filings for updates on the deployment of capital into acquisitions or general corporate purposes.